insights_auto
Why is NTLA up 5,34%?
Dive Deeperchevron_right
NTLA:NASDAQ
Intellia Therapeutics Inc
US$12,03
arrow_upward
+5,34%(+0,61) 1D
US$11,95
arrow_downward
-0,67% (-0,080)bedtimeAfter hours
Closed: 29 ກ.ຍ., 16 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NTLA...
Open
US$11,49
High
US$12,05
Low
US$11,42
Mkt. cap
1,69 ຕື້
Avg. vol.
3,81 ລ້ານ
Volume
5,02 ລ້ານ
52-wk high
US$28,24
52-wk low
US$7,95
EPS
US$-3,36
Beta
1,82
Shares outstanding
140,13 ລ້ານ
No. of employees
377
Open
US$11,49
High
US$12,05
Low
US$11,42
Mkt. cap
1,69 ຕື້
Avg. vol.
3,81 ລ້ານ
Volume
5,02 ລ້ານ
52-wk high
US$28,24
52-wk low
US$7,95
EPS
US$-3,36
Beta
1,82
Shares outstanding
140,13 ລ້ານ
No. of employees
377
News stories
From web sources and news partners
Yahoo Finance
·
10 ຊົ່ວໂມງກ່ອນ
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Yahoo Finance
·
2 ມື້ກ່ອນ
Could This Cathie Wood Stock Soar in 2027?
Seeking Alpha
·
2 ມື້ກ່ອນ
Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn! (NASDAQ:NTLA)
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees377
Founded2014
Headquartersແຄມບຣິກ, ມາຊາຊູເຊັດ, ສະຫະລັດ
SectorBiotechnology
Websiteintelliatx.com